Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK study of repeated IV NPC-06 on amenamevir in healthy Japanese males
jRCT2031220593Phase 1Active, not recruiting
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Jan 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fosphenytoin in herpes zoster (HZ), sponsored by Nobelpharma Co., Ltd. Primary endpoints: Plasma amenamevir concentrations, Plasma total fosphenytoin concentrations and 3 more. Started Jan 2023; status: active, not recruiting.
02
Drugs
fosphenytoin
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on jRCT2031220593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220593.